April 15, 2024
2 min watch
Save
VIDEO: Neurotech prepares to submit license application for NT-501
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Richard Small, CEO of Neurotech Pharmaceuticals, gives an update on encapsulated cell therapy for the extended treatment of retinal diseases.
Following two successful phase 3 studies, Neurotech is preparing to submit a license application for NT-501 to the FDA “very soon.”
Small also discusses the company’s efforts to build on its infrastructure and manufacturing capabilities ahead of the submission.
Editor's note: The headline and article were updated on April 16, 2024, to clarify the license application.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Small reports being the CEO of Neurotech Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.